151 related articles for article (PubMed ID: 17051658)
1. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors.
Andrews MJ; Kontopidis G; McInnes C; Plater A; Innes L; Cowan A; Jewsbury P; Fischer PM
Chembiochem; 2006 Dec; 7(12):1909-15. PubMed ID: 17051658
[TBL] [Abstract][Full Text] [Related]
2. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.
Andrews MJ; McInnes C; Kontopidis G; Innes L; Cowan A; Plater A; Fischer PM
Org Biomol Chem; 2004 Oct; 2(19):2735-41. PubMed ID: 15455144
[TBL] [Abstract][Full Text] [Related]
4. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
5. CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads.
Castanedo G; Clark K; Wang S; Tsui V; Wong M; Nicholas J; Wickramasinghe D; Marsters JC; Sutherlin D
Bioorg Med Chem Lett; 2006 Mar; 16(6):1716-20. PubMed ID: 16384702
[TBL] [Abstract][Full Text] [Related]
6. Rational design of a cyclin A fluorescent peptide sensor.
Pazos E; Pérez M; Gutiérrez-de-Terán H; Orzáez M; Guevara T; Mascareñas JL; Vázquez ME
Org Biomol Chem; 2011 Oct; 9(22):7629-32. PubMed ID: 21863156
[TBL] [Abstract][Full Text] [Related]
7. A novel method for evaluation and screening of caspase inhibitory peptides by the amino acid positional fitness score.
Yoshimori A; Takasawa R; Tanuma S
BMC Pharmacol; 2004 May; 4():7. PubMed ID: 15154972
[TBL] [Abstract][Full Text] [Related]
8. Beta-hairpin peptidomimetics: design, structures and biological activities.
Robinson JA
Acc Chem Res; 2008 Oct; 41(10):1278-88. PubMed ID: 18412373
[TBL] [Abstract][Full Text] [Related]
9. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange.
Kontopidis G; Andrews MJ; McInnes C; Cowan A; Powers H; Innes L; Plater A; Griffiths G; Paterson D; Zheleva DI; Lane DP; Green S; Walkinshaw MD; Fischer PM
Structure; 2003 Dec; 11(12):1537-46. PubMed ID: 14656438
[TBL] [Abstract][Full Text] [Related]
10. E-novo: an automated workflow for efficient structure-based lead optimization.
Pearce BC; Langley DR; Kang J; Huang H; Kulkarni A
J Chem Inf Model; 2009 Jul; 49(7):1797-809. PubMed ID: 19552372
[TBL] [Abstract][Full Text] [Related]
11. Use of phage display and polyvalency to design inhibitors of protein-protein interactions.
Mourez M; Collier RJ
Methods Mol Biol; 2004; 261():213-28. PubMed ID: 15064461
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping.
Richardson CM; Nunns CL; Williamson DS; Parratt MJ; Dokurno P; Howes R; Borgognoni J; Drysdale MJ; Finch H; Hubbard RE; Jackson PS; Kierstan P; Lentzen G; Moore JD; Murray JB; Simmonite H; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2007 Jul; 17(14):3880-5. PubMed ID: 17570665
[TBL] [Abstract][Full Text] [Related]
13. Comparison of mRNA-display-based selections using synthetic peptide and natural protein libraries.
Huang BC; Liu R
Biochemistry; 2007 Sep; 46(35):10102-12. PubMed ID: 17685586
[TBL] [Abstract][Full Text] [Related]
14. Amino acid requirement for the high affinity binding of a selected arginine-rich peptide with the HIV Rev-response element RNA.
Sugaya M; Nishino N; Katoh A; Harada K
J Pept Sci; 2008 Aug; 14(8):924-35. PubMed ID: 18351707
[TBL] [Abstract][Full Text] [Related]
15. Structure-guided discovery of cyclin-dependent kinase inhibitors.
Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
[TBL] [Abstract][Full Text] [Related]
16. LigEvolutioner, a new strategy for modification and optimization of lead compounds in receptor/ligand complexes.
Zhou P; Tian F; Shang Z
Chem Biol Drug Des; 2008 Dec; 72(6):525-32. PubMed ID: 19090919
[TBL] [Abstract][Full Text] [Related]
17. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening studies to design potent CDK2-cyclin A inhibitors.
Vadivelan S; Sinha BN; Irudayam SJ; Jagarlapudi SA
J Chem Inf Model; 2007; 47(4):1526-35. PubMed ID: 17523616
[TBL] [Abstract][Full Text] [Related]
19. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
Kontopidis G; McInnes C; Pandalaneni SR; McNae I; Gibson D; Mezna M; Thomas M; Wood G; Wang S; Walkinshaw MD; Fischer PM
Chem Biol; 2006 Feb; 13(2):201-11. PubMed ID: 16492568
[TBL] [Abstract][Full Text] [Related]
20. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
Card GL; Blasdel L; England BP; Zhang C; Suzuki Y; Gillette S; Fong D; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
Nat Biotechnol; 2005 Feb; 23(2):201-7. PubMed ID: 15685167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
